Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ TMF AMP
5 things to watch on the ASX 200 on Tuesday
⏸️ TMF AMP
ASX 200 starts the week strongly, up 1.3%
⏸️ TMF AMP
ASX 200 storms 1.2% higher: Cochlear reports 60% sales decline, Webjet jumps 22%
Share Fallers
Cochlear share price lower after reporting 60% sales decline in April
⏸️ ASX Shares
3 top ASX 200 shares to buy right now
Share Market News
2 blue chip ASX healthcare shares to buy right now
Capital Raising
Here are all the ASX 200 companies that have announced capital raisings so far in 2020
⏸️ ASX Shares
3 small cap ASX healthcare shares with enormous potential
Share Gainers
Broker calls time on this top performing ASX healthcare stock
Share Market News
Why I'm holding onto my Pointsbet shares
Coronavirus News
5 quality ASX shares to buy in this once-in-a-lifetime opportunity
Share Market News
Top brokers name 3 ASX shares to sell today
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
